Qualification of a Novel Multiplex Assay for the Quantitation of Chemokine Markers in Human Plasma and CSF Samples – NBC 2025

Purpose

Multiplex assays have become an increasingly valuable tool in biomarker analyses. They offer the ability to evaluate multiple targets or analytes simultaneously, while using less sample volume, with decreased time and labor in generating impactful clinical results. Platforms which offer the flexibility of combining multiple biomarkers of interest for a particular disease on the same assay can be even more valuable. Additionally, assays which have been characterized in multiple matrices, such as plasma, serum, CSF, urine, etc. can provide additional value of disease state or drug effect between the various physiological compartments, which may improve understanding of biological interactions and target mediated effects. Here we have optimized and qualified a method to measure 7 individual chemokines, implicated in various autoinflammatory, oncological, and neurodegenerative indications, in both plasma and cerebrospinal fluid (CSF). The successful use of this method will generate useful data for multiple purposes, including characterization of disease state, definition of the relationship between peripheral and CNS, as well as measurement of drug effects.